Financial assistance and support

Interconnect offers financial assistance and support options to help make your prescribed treatment more affordablea

Your Care Manager Team will work with you to help you find financial support options for LYNAVOY (linerixibat). From understanding your insurance benefits to navigating financial support options, we are here to help every step of the way.

Exploring your options

Assistance with access to LYNAVOY

  • If you are currently
    commercially insured:

    If you are eligible, we’ll enroll you in a program that can help you get as little as a $0 copay.b

  • If you have Medicare
    or Medicaid:

    Assistance may be available through independent foundations.c

  • If you have no insurance or limited coverage for LYNAVOY:

    If qualified, you may be able to have access to your treatment at no cost.a,b,c Your Care Manager Team can help you find out if you’re eligible.

aEligibility rules apply.

bOffer not valid for patients enrolled in Medicare, Medicaid, VA, DoD, Tricare, or other federal or state healthcare programs.
For program terms, conditions, and eligibility criteria, click here.

cIndependent foundations are not associated with Alfasigma Pharmaceuticals. Specific details and eligibility requirements can be found directly at the foundations’ websites. Alfasigma does not endorse or guarantee reimbursement or support from any independent charitable organization.

You are now leaving Interconnect

Any information you provide after you leave this site and enter another site will be subject to the other website’s privacy policy and terms and conditions. Interconnect is not responsible for the use, security, or disclosure of any information you may provide to another site.

The information on this site is intended for healthcare professionals in the United States, its territories, and Puerto Rico, and is not intended for the general public.

Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., has voluntarily withdrawn OCALIVA® (obeticholic acid) from the market for the treatment of primary biliary cholangitis (PBC), effective November 14.

Patients should talk to their healthcare professionals and may also contact Intercept's patient support services (Interconnect at 1-844-622-4278) through December 31, 2025.

Interconnect's website is being temporarily maintained and is no longer fully functional for enrollment purposes due to the withdrawal of OCALIVA.

Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or 1-844-782-4278. Additionally, patients or healthcare professionals may request Full Prescribing Information or the OCALIVA Medication Guide by contacting medinfo@interceptpharma.com.

For all other inquiries please contact: info@interceptpharma.com